Specific Diagnostics, a Mountain View, CA-based developer of in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture, received $12.5M investment from Telegraph Hill Partners.
In conjunction with the funding, Dr. Paul Grossman, Ph.D., J.D. of THP, is joining Specific’s Board of Directors.
The company intends to use the funds for the commercialization of its platform.
Led by Dr. Paul Rhodes, Ph.D., CEO, Specific Diagnostics has developed Reveal, a patented chemical sensor array technology platform that detects growth and quantifies antibiotic efficacy with automated instruments and disposables. The company promises that its system provides antibiotic susceptibility results in hours instead of days. Specific will now progress to clinical studies and prepare Reveal for the market, both in Europe and the United States.
The company also has offices in Cambridge, UK.